GHK-Cu is a copper complex of the tripeptide glycine-histidine-lysine. Its research literature includes cell experiments, animal wound models and studies of particular topical regimens. Those are different bodies of evidence. A result for one preparation should not be presented as a demonstrated outcome for every material sold or described under the same name.

This dossier examines selected primary-source records rather than attempting an exhaustive literature review. The older experimental findings are useful for understanding the research questions. They do not remove the need to check a modern formulation or a new outcome claim on its own evidence.

GHK, GHK-Cu and modified delivery materials

The letters GHK specify glycine, histidine and lysine in that order. GHK-Cu includes copper association. A chemically modified derivative or a carrier containing peptide introduces further distinctions. Record the exact material before comparing experiments; a word such as copper peptide is too broad to resolve its composition.

AHK-Cu has alanine in the first position rather than glycine. Keep its studies in the AHK-Cu dossier. A related sequence can motivate a comparison, but similarity does not make two compounds interchangeable. The peptide classification guide explains how complexes and derivatives fit into an identity record.

What selected GHK-Cu studies measured

Scroll horizontally to read all columns.

Primary recordMaterial and modelFinding and boundary
Maquart et al., 1988GHK-Cu in fibroblast culturesReported increased collagen synthesis; a cultured-cell response
Maquart et al., 1993GHK-Cu in rat experimental wound chambersReported changes in connective-tissue accumulation; an animal wound model
Miller et al., 2006Topical regimens with or without GHK-Cu after CO2 laser resurfacing13 completers; no significant between-group differences in the reported objective measures, with a questionnaire difference

The table is a source map, not a pooled effect estimate. The studies differ in model and intervention, so their results should not be combined into a single percentage benefit. The summaries below are based on the linked publication abstracts; detailed risk-of-bias assessment would require the full study reports.

Cell and animal findings concern their measured systems

In the 1988 fibroblast study, investigators reported stimulation of collagen synthesis by GHK-Cu in cell culture. That is evidence for a response in the tested system. It does not measure wrinkles, cosmetic satisfaction or clinical wound closure in people.

The 1993 rat study used experimental wound chambers and examined connective-tissue-related measurements, including collagen and other components. Its model allowed the authors to investigate tissue accumulation. A wound chamber is a specific experimental environment; its result cannot be used as a direct estimate for a topical consumer product.

The next question is whether a study measured the endpoint relevant to the claim being made. A biological mechanism can help explain a hypothesis without establishing that a finished product achieves a useful outcome. Read preclinical versus clinical peptide evidence when those levels are being merged.

The small human laser-resurfacing trial

The 2006 randomized study compared post-laser skin regimens with or without GHK-Cu; 13 patients completed it. The abstract reports no statistically significant between-group differences in earlier erythema resolution or the reported wrinkle and overall-skin-quality assessments. A patient questionnaire favored the GHK-Cu regimen for perceived improvement in overall skin quality, with P = .04.

Keep the questionnaire finding beside the other results. The trial does not support saying that every assessed outcome improved more with GHK-Cu. Its small size and procedure-specific setting also limit how confidently a reader can generalize. A nonsignificant result does not prove equivalence or prove that an effect is impossible.

A hydrogel paper that concerns GHK-C16

The 2023 hyaluronic-acid hydrogel paper describes amphiphilic GHK-C16 nanofibers in a photo-crosslinkable carrier. That is not the same tested material as free GHK-Cu. It belongs in a discussion of modified peptide delivery systems, with its molecular and carrier context retained.

Correction to this dossier, 29 October 2026: the earlier description called that paper a Cu-GHK material study. The linked abstract identifies GHK-C16; the description has been corrected. Its results should not be counted as direct evidence for the copper complex.

How to assess a new GHK-Cu claim

First match the claim to the tested molecular form and formulation. Then identify the comparator, endpoint and observation window. For a human study, inspect who was enrolled, who was analyzed and what unwanted outcomes were reported. For a material study, ask what role the carrier or other components played in the comparison.

A sample certificate answers another question: which analytical attributes were measured for submitted material. The peptide COA checklist and identity-testing guide explain how to read that evidence. Neither an ingredient name nor a study citation verifies the contents of an unrelated container.

For the broader skin-care context, read skin-care peptides and evidence. For a first explanation of why research records and medicine claims need different evidence, start with what research peptides are. This dossier does not recommend a preparation, dose or administration route.